|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment显示文摘Objective:Anlotinib hydrochloride is a multitarget tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor,fibroblast growth factor receptor,platelet-derived growth factor receptor,c-Kit,and c-MET;therefore,it exhibits both antitumor and anti-angiogenetic activities.A phase III trial has shown that anlotinib improved progression-free survival(PFS)and overall survival(OS)in patients with advanced non-small cell lung cancer(NSCLC),who presented with progressive disease or intolerance after standard chemotherapy.This study aimed to analyze the characteristics of patients receiving anlotinib treatment to determine the dominant populations who are fit for the treatment.Methods:Data were collected from March 2015 to January 2017 from a randomized,double-blind,placebo-controlled,multicenter,phase III trial of anlotinib(ALTER0303).A total of 437 patients were enrolled and randomly allocated(2:1)to the anlotinib and placebo groups.Kaplan–Meier analysis and log-rank test were performed to compare PFS and OS.Cox proportional hazards model was adopted for multivariate prognostic analysis.Results:Multivariate analysis indicated that high post-therapeutic peripheral blood granulocyte/lymphocyte ratio and elevated alkaline phosphatase levels were independent risk factors for PFS.Meanwhile,elevated thyroid-stimulating hormone,blood glucose,and triglyceride levels;hypertension;and hand–foot syndrome were independent protective factors of PFS.High posttherapeutic peripheral blood granulocyte/lymphocyte ratio,an Eastern Cooperative Oncology Group(ECOG)score≥2,and the sum of the maximal target lesion length at baseline were independent risk factors of OS,and hypertriglyceridemia was an independent protective factor of OS.Conclusions:This study preliminarily explored the possible factors that affected PFS and OS after anlotinib treatment in patients with advanced refractory NSCLC,and the baseline characteristics of the therapeutically dominant populations were then identified. | Jing Wang Yizhuo Zhao Qiming Wang Li Zhang Jianhua Shi Zhehai Wang Ying Cheng Jianxing He Yuankai Shi Hao Yu Yang Zhao Weiqiang Chen Yi Luo Xiuwen Wang Kejun Nan Faguang Jin Jian Dong Baolan Li Zhujun Liu Baohui Han Kai Li | 2018 | Cancer Biology & Medicine2018，15，4： | 46 |
| 2 | Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin:Analysis of 1,085 WHO classified cases in a single institution in China显示文摘Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma(DLBCL)patients in China according to the primary site.Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site.Results: In the 1,085 patients, 679(62.6%) cases were nodal DLBCL(N-DLBCL) and 406 cases(37.4%) were extranodal DLBCL(EN-DLBCL). The most common sites of N-DLBCL were lymphonodus(64.8%), Waldeyer's ring(19.7%), mediastinum(12.8%) and spleen(2.7%), while in EN-DLBCL, stomach(22.4%), intestine(16.0%),nose and sinuses(8.9%), testis(8.4%), skin(7.9%), thyroid(6.9%), central nervous system(CNS)(6.4%), breast(5.7%), bone(3.4%), and salivary gland(2.7%) were most common. N-DLBCL patients tend to present B symptoms, bulky disease, and elevated LDH more often, while age >60 years, extranodal sites >1, Ann Arbor stage I or II, bone marrow involvement, and Ki-67 index >90% were usually seen in EN-DLBCL. The 5-year overall survival(OS) rate and progression-free survival(PFS) rate for all patients were 62.5% and 54.2%. The 5-year OS rate for patients with N-DLBCL and EN-DLBCL were 65.5% and 56.9%(P=0.008), and the 5-year PFS were57.0% and 49.0%(P=0.020). Waldeyer's ring originated DLBCL possessed the highest 5-year OS rate(83.6%) and PFS rate(76.9%) in N-DLBCL. The top five EN-DLBCL subtypes with favorable prognosis were stomach,breast, nose and sinuses, lung, salivary gland, with 5-year OS rate: 70.3%, 69.6%, 69.4%, 66.7% and 63.6%,respectively. While CNS, testis, oral cavity and kidney originated EN-DLBCL faced miserable prognosis, with 5-year OS rate of 26.9%, 38.2%, and 42.9%.Conclusions: In our study, primary sites were associated with clinical characteristics and outcomes. Compared with EN-DLBCL, N-DLBCL had better prognosis. | Yuankai Shi Ying Han Jianliang Yang Peng Liu Xiaohui He Changgong Zhang Shengyu Zhou Liqiang Zhou Yan Qin Yongwen Song Yueping Liu Shulian Wang Jing Jin Lin Gui Yan Sun | 2019 | Chinese Journal of Cancer Research2019，31，1： | 19 |
| 3 | Forecasting Method of Stock Market Volatility in Time Series Data Based on Mixed Model of ARIMA and XGBoost显示文摘Stock price forecasting is an important issue and interesting topic in financial markets.Because reasonable and accurate forecasts have the potential to generate high economic benefits,many researchers have been involved in the study of stock price forecasts.In this paper,the DWT-ARIMAGSXGB hybrid model is proposed.Firstly,the discrete wavelet transform is used to split the data set into approximation and error parts.Then the ARIMA(0,1,1),ARIMA(1,1,0),ARIMA(2,1,1)and ARIMA(3,1,0)models respectively process approximate partial data and the improved xgboost model(GSXGB)handles error partial data.Finally,the prediction results are combined using wavelet reconstruction.According to the experimental comparison of 10 stock data sets,it is found that the errors of DWT-ARIMA-GSXGB model are less than the four prediction models of ARIMA,XGBoost,GSXGB and DWT-ARIMA-XGBoost.The simulation results show that the DWT-ARIMA-GSXGB stock price prediction model has good approximation ability and generalization ability,and can fit the stock index opening price well.And the proposed model is considered to greatly improve the predictive performance of a single ARIMA model or a single XGBoost model in predicting stock prices. | Yan Wang Yuankai Guo | 2020 | China Communications2020，17，3： | 15 |
| 4 | A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor(PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia显示文摘Objective: The recommended dose of prophylactic pegylated recombinant human granulocyte-colony stimulating factor(PEG rhG-CSF) is 100 μg/kg once per cycle for patients receiving intense-dose chemotherapy.However, few data are available on the proper dose for patients receiving less-intense chemotherapy. The aim of this phase I study is to explore the proper dose and administration schedule of PEG rhG-CSF for patients receiving standard-dose chemotherapy.Methods:Eligible patients received 3-cycle chemotherapy every 3 weeks.No PEG rhG-CSF was given in the first cycle.Patients experienced grade 3 or 4 neutropenia would then enter the cycle 2 and 3.In cycle 2,patients received a single subcutaneous injection of prophylactic PEG rhG-CSF on d 3,and received half-dose subcutaneous injection in cycle 3 on d 3 and d 5,respectively.Escalating doses(30,60,100 and 200μg/kg)of PEG rhG-CSF were investigated.Results:A total of 26 patients were enrolled and received chemotherapy,in which 24 and 18 patients entered cycle 2 and cycle 3 treatment,respectively.In cycle 2,the incidence of grade 3 or 4 neutropenia for patients receiving single-dose PEG rhG-CSF of 30,60,100 and 200 μg/kg was 66.67%,33.33%,22.22% and 0,respectively,with a median duration less than 1(0–2)d.No grade 3 or higher neutropenia was noted in cycle 3 in all dose cohorts.Conclusions:The pharmacokinetic and pharmacodynamic profiles of PEG rhG-CSF used in cancer patients were similar to those reported,as well as the safety.Double half dose administration model showed better efficacy result than a single dose model in terms of grade 3 neutropenia and above.The single dose of 60 μg/kg,100 μg/kg and double half dose of 30 μg/kg were recommended to the phase Ⅱ study,hoping to find a preferable method for neutropenia treatment. | Yan Qin Xiaohong Han Lin Wang Ping Du Jiarui Yao Di Wu Yuanyuan Song Shuxiang Zhang Le Tang Yuankai Shi | 2017 | Chinese Journal of Cancer Research2017，29，5： | 11 |
| 5 | Aeration optimization through operation at low dissolved oxygen concentrations:Evaluation of oxygen mass transfer dynamics in different activated sludge systems显示文摘In wastewater treatment plants(WWTPs)using the activated sludge process,two methods are widely used to improve aeration efficiency — use of high-efficiency aeration devices and optimizing the aeration control strategy. Aeration efficiency is closely linked to sludge characteristics(such as concentrations of mixed liquor suspended solids(MLSS)and microbial communities)and operating conditions(such as air flow rate and operational dissolved oxygen(DO)concentrations). Moreover,operational DO is closely linked to effluent quality. This study,which is in reference to WWTP discharge class A Chinese standard effluent criteria,determined the growth kinetics parameters of nitrifiers at different DO levels in small-scale tests. Results showed that the activated sludge system could meet effluent criteria when DO was as low as 0.3 mg/L,and that nitrifier communities cultivated under low DO conditions had higher oxygen affinity than those cultivated under high DO conditions,as indicated by the oxygen half-saturation constant and nitrification ability. Based on nitrifier growth kinetics and on the oxygen mass transfer dynamic model(determined using different air flow rate(Q′_(air))and mixed liquor volatile suspended solids(MLVSS)values),theoretical analysis indicated limited potential for energy saving by improving aeration diffuser performance when the activated sludge system had low oxygen consumption; however,operating at low DO and low MLVSS could significantly reduce energy consumption. Finally,a control strategy coupling sludge retention time and MLVSS to minimize the DO level was discussed,which is critical to appropriate setting of the oxygen point and to the operation of low DO treatment technology. | Haitao Fan Lu Qi Guoqiang Liu Yuankai Zhang Qiang Fan Hongchen Wang | 2017 | Journal of Environmental Sciences2017，29，5： | 9 |
| 6 | Analysis of key microbial community during the start-up of anaerobic ammonium oxidation process with paddy soil as inoculated sludge显示文摘A sequencing batch reactor(SBR)-anaerobic ammonium oxidation(anammox) system was started up with the paddy soil as inoculated sludge. The key microbial community structure in the system along with the enrichment time was investigated by using molecular biology methods(e.g., high-throughput 16 S r RNA gene sequencing and quantitative PCR). Meanwhile,the influent and effluent water quality was continuously monitored during the whole start-up stage. The results showed that the microbial diversity decreased as the operation time initially and increased afterwards, and the microbial niches in the system were redistributed. The anammox bacterial community structure in the SBR-anammox system shifted during the enrichment, the most dominant anammox bacteria were Candidatus Jettenia. The maximum biomass of anammox bacteria achieved 1.68 × 10~9 copies/g dry sludge during the enrichment period, and the highest removal rate of TN achieved around 75%. | Xianglong Xu Guohua Liu Yuanyuan Wang Yuankai Zhang Hao Wan Lu Qi Hongchen Wang | 2018 | Journal of Environmental Sciences2018，30，2： | 8 |
| 7 | Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer:an open-label,randomized controlled phase 3 trial(ORIENT-3)显示文摘Background:Treatment options for Chinese patients with locally advanced or metastatic squamous-cell non-small-cell lung cancer(sqNSCLC)after failure of first-line chemotherapy are limited.This study(ORIENT-3)aimed to evaluate the efficacy and safety of sintilimab versus docetaxel as second-line treatment in patients with locally advanced or metastatic sqNSCLC.Methods:ORIENT-3 was an open-label,multicenter,randomized controlled phase 3 trial that recruited patients with stage IIIB/IIIC/IV sqNSCLC after failure with first-line platinum-based chemotherapy.Patients were randomized in a 1:1 ratio to receive either 200 mg of sintilimab or 75 mg/m^(2) of docetaxel intravenously every 3 weeks,stratified by the Eastern Cooperative Oncology Group performance status.The primary endpoint was overall survival(OS)in the full analysis set(FAS).Secondary endpoints included progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),duration of response(DoR)and safety.Results:Between August 25,2017,and November 7,2018,290 patients were randomized.For FAS,10 patients fromthe docetaxel armwere excluded.Themedian OS was 11.79(n=145;95%confidence interval[CI],10.28-15.57)months with sintilimab versus 8.25(n=135;95%CI,6.47-9.82)months with docetaxel(hazard ratio[HR]:0.74;95%CI,0.56-0.96;P=0.025).Sintilimab treatment significantly prolonged PFS(median 4.30 vs.2.79 months;HR:0.52;95%CI,0.39-0.68;P<0.001)and showed higher ORR(25.50%vs.2.20%,P<0.001)and DCR(65.50%vs.37.80%,P<0.001)than the docetaxel arm.The median DoRwas 12.45(95%CI,4.86-25.33)months in the sintilimab arm and 4.14(95%CI,1.41-7.23)months in the docetaxel arm(P=0.045).Treatment-related adverse events of grade≥3were reported in 26(18.1%)patients in the sintilimab arm and 47(36.2%)patients in the docetaxel arm.Exploratory biomarker analysis showed potential predictive values of expression levels of two transcription factors,including OVOL2(HR:0.35;P<0.001)and CTCF(HR:3.50;P<0.001),for sintilimab treatment.Conclusions:Compared with docetaxel,sintilimab significantly improved the OS,PFS,and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC. | Yuankai Shi Lin Wu Xinmin Yu Puyuan Xing Yan Wang Jianying Zhou Airong Wang Jianhua Shi Yi Hu Ziping Wang Guangyu An Yong Fang Sanyuan Sun Caicun Zhou Changli Wang Feng Ye Xingya Li Junye Wang Mengzhao Wang Yunpeng Liu Yanqiu Zhao Ying Yuan Jifeng Feng Zhendong Chen Jindong Shi Tao Sun Gang Wu Yongqian Shu Qisen Guo Yi Zhang Yong Song Shucai Zhang Yuan Chen Wei Li Hongrui Niu Wenwei Hu Lijun Wang Jianan Huang Yang Zhang Ying Cheng Zhengdong Wu Bo Peng Jiya Sun Christoph Mancao Yanqi Wang Luyao Sun | 2022 | Cancer Communications2022，42，12： | 8 |
| 8 | A phaseⅠtrial of an oral subtype-selective histone deacetylase inhibitor,chidamide,in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer显示文摘Objective: This phase Ⅰ study was to evaluate safety, maximum tolerated dose, pharmacokinetics and preliminary antitumor activity of chidamide, a novel subtype-selective histone deacetylase(HDAC) inhibitor, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer(NSCLC).Methods: Ten patients received oral chidamide 20, 25, or 30 mg twice per week continuously with paclitaxel(175 mg/m^2) and carboplatin [area under the curve(AUC) 5 mg/m L/min] administered in a 3-week cycle. Patients with response and stable disease after four cycles maintained chidamide monotherapy until disease progression or unacceptable toxicity. Blood samples were collected for pharmacokinetic analysis after the first single oral of chidamide and first combination treatment in cycle 1 from all patients.Results: Two dose-limiting toxicities were recorded in the 30 mg cohort, including thrombocytopenia and prolonged neutropenia in the first cycle. Grade 3/4 neutropenia in any cycle was observed in all patients, but was not associated with significant complications. Other grade 3/4 hematologic toxicities included thrombocytopenia and leucopenia. No significant changes were observed in pharmacokinetic parameters for both chidamide and paclitaxel. One patient in the 20 mg cohort had confirmed partial response(PR). Two out of 5 patients with brain metastases had intracranial complete remission after 4-cycle treatment.Conclusions: Chidamide combined with paclitaxel and carboplatin was generally tolerated without unanticipated toxicities or clinically relevant pharmacokinetic interactions. The recommended dose for chidamide in this combination was established at 20 mg, and a phase Ⅱ trial is ongoing with this regimen in patients with advanced NSCLC. | Xingsheng Hu Lin Wang Lin Lin Xiaohong Han Guifang Dou Zhiyun Meng Yuankai Shi | 2016 | Chinese Journal of Cancer Research2016，28，4： | 6 |
| 9 | Current state and future perspectives of sewer networks in urban China显示文摘中国当局和公众大部分忽略了下水道网络;然而,各种各样的问题与新下水道的增加构造全国正在出现。在中国的下水道网络建设,管理,和维护的当前的国家包括地在这研究被考察。为大约 4.44 亿个人,服务下水道线的 511,200 km 位于城市的区域。在 2014, 70 亿美元在下水道网络建设被投资。然而,下水道扩散率和人均的下水道长度是比在发达国家的那些显著地低的。在本地政府的下水道行政机构是不协调的。法律,规定,和标准是不完全的,并且一些惯例是非科学的。因为下水道腐蚀控制措施没被发射,下水道维护的未来状况是极其冷酷的。而且,检查和康复主要依靠传统的途径。相反,创新技术的全面市场份额由于高费用,资金缺乏,和技术限制是很低的。象班机倒置 cured-in-place 那样的途径尖叫,开车进入用餐的餐厅紫外轻治好的班机,和螺线创伤衬里主要在经济地发达的区域被使用。根据地位和问题分析,瓷器最高的优先级将是以后在下水道网络进行好攻击的维护工作。新技术线路,腐蚀控制 - 周期的设想的检查 - 无沟的康复,能是为在中国的未来下水道维护的最好的选择。为使用这条技术线路的指令和机会在这研究详细被讨论。最后,在在中国的下水道网络的开发的另外的因素被建议。 | Dong Huang Xiuhong Liu Songzhu Jiang Hongchen Wang Junyan Wang Yuankai Zhang | 2018 | Frontiers of Environmental Science & Engineering2018，12，3： | 5 |
| 10 | Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma显示文摘Objective: To assess the clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma(DLBCL).Methods: A retrospective study of 37 patients with primary testicular DLBCL was carried out from November 2003 to May 2012. Their clinical features, survival and prognostic factors were analyzed.Results: During a median follow-up period of 39.8 months(5.4-93.0 months), the median progression-free survival(PFS) was 26.2 months(95% CI: 0-65 months) and the 3-year overall survival(OS) rate was 78.4%. Within the whole cohort, the factors significantly associated with a superior PFS were limited stage(stage I/II), lactate dehydrogenase(LDH) ≤245 U/L, international prognostic index(IPI) ≤1, primary tumor diameter <7.5 cm, and patients who had complete response(CR) and received doxorubicin-contained chemotherapy(P<0.05). There was a trend toward superior outcome for patients who received combined therapy(surgery/chemotherapy/radiotherapy)(P=0.055). Patients who had CR, primary tumor diameter <7.5 cm and IPI score ≤1 were significantly associated with longer PFS at multivariate analysis.Conclusions: Primary testicular DLBCL had poorer survival. CR, primary tumor diameter and IPI were independent prognostic factors. The combined therapy of orchectomy, doxorubicin-contained chemotherapy and contralateral testicular radiotherapy(RT) seemed to improve survival. | Bo Jia Yuankai Shi Mei Dong Fengyi Feng Sheng Yang Hua Lin Liqiang Zhou Shengyu Zhou Shanshan Chen Jianliang Yang Peng Liu Yan Qin Changgong Zhang Lin Gui Lin Wang Xue Wang Xiaohui He | 2014 | Chinese Journal of Cancer Research2014，26，4： | 5 |
| 11 | Bevacizumab biosimilar LY01008 compared with bevacizumab(Avastin)as first-line treatment for Chinese patients with unresectable,metastatic,or recurrent non-squamous non-small-cell lung cancer:A multicenter,randomized,double-blinded,phase Ⅲ trial显示文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting. | Yuankai Shi Kaijian Lei Yuming Jia Bingqiang Ni Zhiyong He Minghong Bi Xicheng Wang Jianhua Shi Ming Zhou Qian Sun Guolei Wang Dongji Chen Yongqian Shu Lianke Liu Zhongliang Guo Yong Liu Junquan Yang Ke Wang Ke Xiao LinWu Tienan Yi Debin Sun Mafei Kang Tianjiang Ma Yimin Mao Jinsheng Shi Tiegang Tang Yan Wang Puyuan Xing Dongqing Lv Wangjun Liao Zhiguo Luo Bin Wang Xiaohong Wu Xiaoli Zhu Shuhua Han Qisen Guo Rongyu Liu Zhiwei Lu Jianyong Zhang Jian Fang Changlu Hu Yinghua Ji Guolong Liu Hong Lu Dedong Wu Junhong Zhang Shuyang Zhu Zheng Liu Wensheng Qiu Feng Ye Yan Yu Yanqiu Zhao Qinhong Zheng Jun Chen Zhanyu Pan Yiping Zhang Wenjuan Lian Bo Jiang Bo Qiu Guojun Zhang Hua Zhang Yanju Chen Yuan Chen Hongbing Duan Manxiang Li Shengming Liu Lijun Ma Hongming Pan Xia Yuan Xueli Yuan Yulong Zheng Emei Gao Li Zhao Shumin Wang Can Wu | 2021 | Cancer Communications2021，41，9： | 5 |
| 12 | Simple model of sludge thickening process in secondary settlers显示文摘在废水处理植物(WWTP ) ,一个第二等的定居者充当 clarifier,污泥 thickener,和污泥存储坦克在期间山峰流动因此在激活的污泥进程的性能起一个重要作用。变厚的污泥在他们的操作期间发生在第二等的 clarifiers 的更低的部分。在这研究,由从激活的污泥的完全的变厚过程检测妨碍的地区,为污泥的一个简单模型变厚的速度, u s =斧子 b (= 0.9925SSVI 3.5, b = 3.541ln (描述在妨碍的地区变厚的激活的污泥的潜力和表演的 SSVI 3.5)+12.973),被开发。然而,因为在压缩地区的污泥显示出有限变厚,在压缩地区变厚的污泥没被学习。这个实验模型用解决从四 WWTP 获得并且从第五 WWTP 用测量数据验证了更好学习污泥变厚的数据的批被开发。探索不同污泥安定和变厚的机制,污泥变厚和污泥安定的曲线被比较。最后,包括温度,激动人心的、起始的深度,和聚合物调节的几个因素能在一个生物学的反应堆导致高度集中的回来污泥和生物资源,这被发现。 | Yuankai ZHANG Hongchen WANG Lu QI Guohua LIU Zhijiang HE Songzhu JIANG | 2016 | Frontiers of Environmental Science & Engineering2016，10，2： | 3 |
| 13 | Nature-inspired surface topography: design and function显示文摘Learning from nature has traditionally and continuously provided important insights to drive a paradigm shift in technology.In particular,recent studies show that many biological organisms exhibit spectacular surface topography such as shape,size,spatial organization,periodicity,interconnectivity,and hierarchy to endow them with the capability to adapt dynamically and responsively to a wide range of environments.More excitingly,in a broader perspective,these normally neglected topological features have the potential to fundamentally change the way of how engineering surface works,such as how fluid flows,how heat is transported,and how energy is generated,saved,and converted,to name a few.Thus,the design of nature-inspired surface topography for unique functions will spur new thinking and provide paradigm shift in the development of the new engineering surfaces.In this review,we first present a brief introduction to some insights extracted from nature.Then,we highlight recent progress in designing new surface topographies and demonstrate their applications in emerging areas including thermal-fluid transport,anti-icing,water harvesting,power generation,adhesive control,and soft robotics.Finally,we offer our perspectives on this emerging field,with the aim to stimulate new thinking on the development of next-generation of new materials and devices,and dramatically extend the boundaries of traditional engineering. | XianTong Yan YuanKai Jin XueMei Chen Chao Zhang ChongLei Hao ZuanKai Wang | 2020 | Science China(Physics,Mechanics & Astronomy)2020，63，2： | 3 |
| 14 | Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma显示文摘Background:The role of rituximab in combination with CHOP regimen in patients with stage I diffuse large B-cell lymphoma(DLBCL) remains to be defined.We aimed to compare CHOP plus rituximab(R-CHOP) with CHOP alone and determine the value of radiotherapy in these patients.Methods:Between 2003 and 2009,140 untreated patients with stage I DLBCL were retrospectively analyzed in this study.Results:Seventy-eight patients were treated in R-CHOP group and 62 in CHOP group.Ninety-one patients received additional radiotherapy at the end of chemotherapy.The different treatment groups were well-balanced with respect to baseline characteristics.Complete response(CR) rate was 77% both in R-CHOP and CHOP groups(P=0.945).After a median follow-up period of 56 months,patients received R-CHOP regimen had similar 5-year progression-free survival(PFS)(76%vs.85%;log-rank P=0.215)and 5-year overall survival(OS)(90%vs.96%;log-rank P=0.175) compared with those with CHOP alone.Patients with radiotherapy had significantly increased 5-year PFS compared with those who had chemotherapy alone(86%vs.71%;log-rank P=0.005).At multivariate analysis,patients who had CR(P=0.008) and received radiotherapy(P=0.003) were significantly associated with superior PFS.Conclusions:CHOP alone could be as effective as R-CHOP regimen and additional radiotherapy would be necessary for stage I or stage I non-bulky DLBCL patients. | Bo Jia Yuankai Shi Suyi Kang Sheng Yang Shaoxuan Hu Yexiong Li Mei Dong Weihu Wang Jianliang Yang Liqiang Zhou Peng Liu Shengyu Zhou Yan Qin Lin Gui Changgong Zhang Hua Lin Shanshan Chen Lin Wang Xiaohui He | 2015 | Chinese Journal of Cancer Research2015，27，5： | 2 |
| 15 | Applications of hollow nanomaterials in environmental remediation and monitoring: A review显示文摘因为他们的高化学、热的稳定性,高特定的表面区域,高孔,低密度,和好 biocompatibility,空 nanomaterials 吸引了重要注意。这些最先进的 nanomaterials 被显示了高效地吸附重金属,和不稳定的危险物质, photodegrade 坚持的器官的污染物质,和另外的混合物,并且使细菌失去活性。如此的性质为环境补习启用了这些材料的使用,例如在水 / 废水处理,土壤补习,空气纯化,并且物质监视等等。没有空结构,空 nanomaterials 由于他们的高活跃的表面区域比那些显示出更高的 photocatalytic 活动,减少了散开抵抗,并且改进了可接近性。并且,做的方法能在可见的光下面进一步改进空 nanomaterials 的 photocatalytic 表演。而且,因为他们的尺寸和形态学帮助决定他们的精确性质,这些材料的合成机制和方法是重要的。这篇文章考察环境应用和这些材料的潜在的风险,除了他们的综合体。最后,进这些材料的发展的眼界被提供。 | Yuankai ZHANG Zhijiang HE Hongchen WANG Lu QI Guohua LIU Xiaojun ZHANG | 2015 | Frontiers of Environmental Science & Engineering2015，9，5： | 2 |
| 16 | Current management of chemotherapy-induced neutropenia in adults:key points and new challenges显示文摘Chemotherapy-induced neutropenia(CIN)is a potentially fatal and common complication in myelosuppressive chemotherapy.The timing and grade of CIN may play prognostic and predictive roles in cancer therapy.CIN is associated with older age,poor functional and nutritional status,the presence of significant comorbidities,the type of cancer,previous chemotherapy cycles,the stage of the disease,specific chemotherapy regimens,and combined therapies.There are many key points and new challenges in the management of CIN in adults including:(1)Genetic risk factors to evaluate the patient’s risk for CIN remain unclear.However,these risk factors urgently need to be identified.(2)Febrile neutropenia(FN)remains one of the most common reasons for oncological emergency.No consensus nomogram for FN risk assessment has been established.(3)Different assessment tools[e.g.,Multinational Association for Supportive Care in Cancer(MASCC),the Clinical Index of Stable Febrile Neutropenia(CISNE)score model,and other tools]have been suggested to help stratify the risk of complications in patients with FN.However,current tools have limitations.The CISNE score model is useful to support decision-making,especially for patients with stable FN.(4)There are still some challenges,including the benefits of granulocyte colony stimulating factor treatment and the optimal antibiotic regimen in emergency management of FN.In view of the current reports,our group discusses the key points,new challenges,and management of CIN. | Committee of Neoplastic Supportive-Care(CONS),China Anti-Cancer Association Committee of Clinical Chemotherapy,China Anti-Cancer Association Yi Ba Yuankai Shi Wenqi Jiang Jifeng Feng Ying Cheng Li Xiao Qingyuan Zhang Wensheng Qiu Binghe Xu Ruihua Xu Bo Shen Zhiguo Luo Xiaodong Xie Jianhua Chang Mengzhao Wang Yufu Li Yuerong Shuang Zuoxing Niu Bo Liu Jun Zhang Li Zhang Herui Yao Conghua Xie Huiqiang Huang Wangjun Liao Gongyan Chen Xiaotian Zhang Hanxiang An Yanhong Deng Ping Gong Jianping Xiong Qinghua Yao Xin An Cheng Chen Yanxia Shi Jialei Wang Xiaohua Wang Zhiqiang Wang Puyuan Xing Sheng Yang Chenfei Zhou | 2020 | Cancer Biology & Medicine2020，17，4： | 2 |
| 17 | Variation in primary sequence and tandem repeat copy number among i-antigens of Ichthyophthirius multifiliis 显示文摘 | Lin Yuankai Lin Tian-Long Wang Chia-Cheng | 2002 | Molecul Biochem Parasitol2002，120，： | 2 |
| 18 | A multi-center,open-label,randomized,parallel-controlled phase II study comparing pharmacokinetic,pharmacodynamics and safety of ripertamab(SCT400)to rituximab(Mab Thera?)in patients with CD20-positive B-cell non-Hodgkin lymphoma显示文摘Objective:This multi-center,open-label,randomized,parallel-controlled phaseⅡstudy aimed to compare the pharmacokinetics(PK),pharmacodynamics(PD)and safety profile of ripertamab(SCT400),a recombinant antiCD20 monoclonal antibody,to rituximab(MabThera^(■))in patients with CD20-positive B-cell non-Hodgkin lymphoma(NHL).Methods:Patients with CD20-positive B-cell NHL who achieved complete remission or unconfirmed complete remission after standard treatment were randomly assigned at a 1:1 ratio to receive a single dose of ripertamab(375mg/m^(2))or rituximab(MabThera^(■),375 mg/m^(2)).PK was evaluated using area under the concentration-time curve(AUC)from time 0 to d 85(AUC_(0-85d)),AUC from time 0 to week 1(AUC0-1 w),AUC from time 0 to week 2(AUC_(0-2 w)),AUC from time 0 to week 3(AUC_(0-3 w)),AUC from time 0 to week 8(AUC_(0-8 w)),maximum serum concentration(C_(max)),terminal half-life(T_(1/2)),time to maximum serum concentration(T_(max))and clearance(CL).Bioequivalence was confirmed if the 90%confidence interval(90%CI)of the geometric mean ratio of ripertamab/rituximab was within the pre-defined bioequivalence range of 80.0%-125.0%.PD,immunogenicity,and safety were also evaluated.Results:From December 30,2014 to November 24,2015,a total of 84 patients were randomized(ripertamab,n=42;rituximab,n=42)and the PK analysis was performed on 76 patients(ripertamab,n=38;rituximab,n=38).The geometric mean ratios of ripertamab/rituximab for AUC_(0-85d),ATC_(0-inf),and Cmaxwere 96.1%(90%CI:87.6%-105.5%),95.9%(90%CI:86.5%-106.4%)and 97.4%(90%CI:91.6%-103.6%),respectively.All PK parameters met the pre-defined bioequivalence range of 80.0%-125.0%.For PD and safety evaluation,there was no statistical difference in peripheral CD 19-positive B-cell counts and CD20-positive B-cell counts at each visit,and no difference in the incidence of anti-drug antibodies was observed between the two groups.The incidences of treatment-emergent adverse events and treatment-related adverse events were also comparable between the two groups.Conclusions:In this study,the PK,PD,immunogenicity,and safety profile of ripertamab(SCT400)were similar to rituximab(MabThera^(■))in Chinese patients with CD20-positive B-cell NHL. | Xiaohong Han Mingzhi Zhang Huaqing Wang Qingyuan Zhang Wei Li Miaowang Hao Yuhuan Gao Jie Jin Hanyun Ren Yun Tang Xiaonan Hong Xiaoyan Ke Hang Su Lin Gui Jianmin Luo Liangzhi Xie Wenlin Gai Yuankai Shi | 2022 | Chinese Journal of Cancer Research2022，34，6： | 1 |
| 19 | ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma显示文摘Objective: The relationship between anaplastic lymphoma kinase(ALK) expression in malignant pleural effusion(MPE) samples detected only by Ventana immunohistochemistry(IHC) ALK(D5F3) and the efficacy of ALKtyrosine kinase inhibitor therapy is uncertain.Methods: Ventana anti-ALK(D5F3) rabbit monoclonal primary antibody testing was performed on 313 cell blocks of MPE samples from Chinese patients with advanced lung adenocarcinoma, and fluorescence in situ hybridization(FISH) was used to verify the ALK gene status in Ventana IHC ALK(D5F3)-positive samples. The follow-up clinical data on patients who received crizotinib treatment were recorded.Results: Of the 313 MPE samples, 27(8.6%) were confirmed as ALK expression-positive, and the Ventana IHC ALK(D5F3)-positive rate was 17.3%(27/156) in wild-type epidermal growth factor receptor(EGFR) MPE samples. Twenty-three of the 27 IHC ALK(D5F3)-positive samples were positive by FISH. Of the 11 Ventana IHC ALK(D5F3)-positive patients who received crizotinib therapy, 2 patients had complete response(CR), 5 had partial response(PR) and 3 had stable disease(SD).Conclusions: The ALK gene expression status detected by the Ventana IHC ALK(D5F3) platform in MPE samples may predict tumor responsiveness to crizotinib in Chinese patients with advanced lung adenocarcinoma. | Zheng Wang Xiaonan Wu Xiaohong Han Gang Cheng Xinlin Mu Yuhui Zhang Di Cui Chang Liu Dongge Liu Yuankai Shi | 2016 | Chinese Journal of Cancer Research2016，28，6： | 1 |
| 20 | Quantitative proteomics revealed extensive microenvironmental changes after stem cell transplantation in ischemic stroke显示文摘The local microenvironment is essential to stem cell-based therapy for ischemic stroke,and spatiotemporal changes of the microenvironment in the pathological process provide vital clues for understanding the therapeutic mechanisms.However,relevant studies on microenvironmental changes were mainly confined in the acute phase of stroke,and long-term changes remain unclear.This study aimed to investigate the microenvironmental changes in the subacute and chronic phases of ischemic stroke after stem cell transplantation.Herein,induced pluripotent stem cells(iPSCs)and neural stem cells(NSCs)were transplanted into the ischemic brain established by middle cerebral artery occlusion surgery.Positron emission tomography imaging and neurological tests were applied to evaluate the metabolic and neurofunctional alterations of rats transplanted with stem cells.Quantitative proteomics was employed to investigate the protein expression profiles in iPSCs-transplanted brain in the subacute and chronic phases of stroke.Compared with NSCs-transplanted rats,significantly increased glucose metabolism and neurofunctional scores were observed in iPSCs-transplanted rats.Subsequent proteomic data of iPSCs-transplanted rats identified a total of 39 differentially expressed proteins in the subacute and chronic phases,which are involved in various ischemic stroke-related biological processes,including neuronal survival,axonal remodeling,antioxidative stress,and mitochondrial function restoration.Taken together,our study indicated that iPSCs have a positive therapeutic effect in ischemic stroke and emphasized the wide-ranging microenvironmental changes in the subacute and chronic phases. | Yao Chen Fahuan Song Mengjiao Tu Shuang Wu Xiao He Hao Liu Caiyun Xu Kai Zhang Yuankai Zhu Rui Zhou Chentao Jin Ping Wang Hong Zhang Mei Tian | 2022 | Frontiers of Medicine2022，16，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员